Improved RNA-based engineering of T lymphocytes with leukemia-specific T cell receptors to redirect their effector functions: towards a clinically safe platform to evaluate efficacy and potential off-target toxicity.
Wilms' tumor (WTl) antigen-targeted dendritic cell vaccination to prevent relapse in patients with acute myeloid leukemia: a multicenter randomized phase II trial.
Maximizing the anti-tumor potency of next-generation dendritic cell vaccines by combining interleukin-15 and in situ silencing of programmed-death ligands.
Immune effector cell therapy for hematological malignancies with a focus on acute myeloid leukemia and multiple myeloma.
Safety and feasibility evaluation of first-in-human interleukin-15-transpresenting Wilms'tumor (WT1) targeting autologous dendritic cell vaccination in cancer patients.
Optimization of chimeric antigen receptor (CAR) design for improved cellular immunotherapy of hematological diseases.
Publication type
|
|
|
|
|